Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.
In order to generate more IO therapies, we first need to get a better grip on the underlying biology.
Update on T cell bispecifics and other key topics in early stage IO development
Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.
Notes on HGSOC, melanoma resistance and the evolution of NSCLC...
Coverage of European Association for Cancer Research EACR cancer genomics conference at Churchill College, Cambridge
Commentary from Day 1-2 of the 3rd EACR meeting on Cancer Genomics